“In recent years, the suppliers of EO Indicator Tape exited the market when components required to make the tape became scarce during the pandemic. In response to this void in the marketplace, Propper dedicated time, effort and resources to meet the challenge of filling the gap and we are very happy to announce that Propper has received FDA clearance for EO Chex. As of today, our product is the only FDA cleared EO Tape available for sale in the United States” – Joe Looney, President & CEO – Medical
According to the U.S. Food and Drug Administration (FDA), roughly 50 percent of all medical devices in the country are sterilized using ethylene oxide. For many of these devices, EO is the only method to effectively sterilize them without damage from the sterilization process. Use EO Chex Tape with Gas-Chex® Internal Indicators and BI-OK® EO Biological Indicator to verify your ethylene oxide cycle meets the criteria for a satisfactory sterilization process.
About EO Chex
EO Chex™ Indicator Tape is a pressure-sensitive tape with Ethylene Oxide (EO) process indicator suitable for use in securing sterilization packaging materials EO processing.
EO Chex Tape conforms to the requirements of ISO 11140-1:2014, Type 1 with the following stated values:
37°C, 600mg/L EO, 25 min, 60% RH
54°C, 600mg/L EO, 20 min, 60% RH
The indicator is suitable for the sterilization cycles found in Table 1.
EO Chex™ Indicator Tape is available for sale from Propper Manufacturing Company or through all major distributors. Contact Propper Manufacturing Company or your distributor representative for contracted pricing.
About: Propper Manufacturing Company is a trusted partner to healthcare professionals worldwide by providing reliable and innovative products, services, and educational resources that promote safety and help reduce healthcare-acquired infections. Propper is committed to using the latest technology and research to continuously improve its products and services while prioritizing exceptional customer service and support.
During the HBCU NY Classic, members of Alpha Phi Alpha Fraternity, Inc., Alpha Kappa Alpha Sorority, Inc., Kappa Alpha Psi Fraternity, Inc., Omega Psi Phi Fraternity, Inc., Delta Sigma Theta Sorority, Inc., Zeta Phi Beta Sorority, Inc., Phi Beta Sigma Fraternity, Inc., Sigma Gamma Rho Sorority, Inc., and Iota Phi Theta Fraternity, Inc., will participate in the World’s Largest Black Greek Stroll Line – a historic event in two ways:
First-Ever in an NFL Stadium: Witness the electrifying energy of the Divine Nine stroll unfold within the iconic MetLife Stadium.
The Divine Nine Unity Stroll will symbolize that the D9 stands in unity to Get Out The Vote. This event kicks off one of the most powerful and impactful voter mobilization campaigns of this historic election season. #d9strongertogether
Show Your D9 Pride and Support Education:
Not only will this event be historic, but the Divine 9 organization with the largest number of strollers will be awarded a $10,000 donation to its Educational Foundation.
Don’t Miss Out!
This is a once-in-a-lifetime opportunity to showcase the Divine Nine spirit, celebrate HBCUs, and see Sean Paul perform on a national platform.
Here’s what makes the HBCU New York Classic even more special:
A Five-Day Festivity: The HBCU New York Classic spans a five-day festivity that showcases the culture and community activities of Historically Black Colleges and Universities (HBCUs), culminating in a football game between two HBCU teams at MetLife Stadium. This yearly event pits teams from the Mid-Eastern Athletic Conference (MEAC) against those from the Southern Intercollegiate Athletic Conference (SIAC) and is organized by Sports Eleven05. The Classic is televised live on CNBC.
Get Out the Vote Campaign: In this election season, the NY HBCU Classic will also serve as a platform to engage the 35,000 fans and tailgaters in one of the largest Get Out The Vote events.
The pre-game will feature the “Divine 9 Classic Stroll Line”. A show of unity and symbolic of “Strolling to the Polls” this will be the very first of its kind to occur in an NFL Stadium. Also, the HBCU community, members of the D9 and other community-based organizations will be on-site for voter registration, to encourage voter mobilization, and solicit election volunteers.
HBCU Reception: The HBCU After Party: begins immediately following the game. 2024 HBCU Cocktail Reception Featuring Music by “The Legendary Chris Washington” Beginning at 7:00, the festivities will be held at the Meadowlands Hilton. Two Meadowlands Plaza, East Rutherford, NJ 07073 Tickets are $125.00 and can be purchased via this linkhttps://bit.ly/2024D9Stroll
Quote:
“MetLife Stadium is honored to host the third annual HBCU New York Classic,” said Ron VanDeVeen, President and CEO of MetLife Stadium. “HBCU New York Classic is an outstanding event and we look forward to welcoming Morehouse College, Howard University and thousands of HBCU alumni and fans to our stadium this September.”
“We are thrilled to host the HBCUNY Classic once again at MetLife Stadium,” said Albert Williams, President & CEO of Sports Eleven05 LLC, the producers of the Classic. “This game not only celebrates the rich athletic traditions of Morehouse and Howard University but also underscores the importance of HBCUs in higher education. It’s an opportunity for alumni, students, and fans to come together in the spirit of camaraderie and competition.”
Visitwww.hbcunyclassic.com for more information and secure your tickets for the HBCU New York Classic!
Join us on September 14th and be a part of this unforgettable event!
About The HBCU New York Classic
The HBCU New York Classic spans a five-day festivity that showcases the culture and community activities of Historically Black Colleges and Universities (HBCUs), culminating in a football game between two HBCU teams at MetLife Stadium. This yearly event pits teams from the Mid-Eastern Athletic Conference (MEAC) against those from the Southern Intercollegiate Athletic Conference (SIAC) and is organized by Sports Eleven05. The classic is televised live on CNBC. For further details and to stay updated on ticket information, please visit www.hbcunyclassic.com.
About MetLife Stadium
MetLife Stadium, located in East Rutherford, NJ, is the home of the New York Jets and New York Football Giants. It is one of the largest stadiums in the NFL with a capacity of 82,500. MetLife Stadium hosts the world’s biggest events on the world’s biggest stage and will serve as host stadium for the FIFA World Cup 2026™ Final. MetLife Stadium has hosted over 550 major events and 3,000 special events. Event highlights include the first outdoor, cold-weather Super Bowl XLVIII, WrestleMania 29 and 35, the Copa America Centenario Final, the 2021 Army-Navy Game, and many concerts, college football games, and international soccer matches.
The new fertility center will be led by Boston IVF reproductive endocrinologists Drs. Emily Seidler and Riwa Sabbagh – who will begin treating patients in Fall 2024. Additionally, Dr. Jill Attaman will join the Concord fertility team in early 2025. Each physician specializes in all aspects of fertility treatment and care.
Sharon Edwards, RN, Boston IVF Chief Operating Officer expressed her enthusiasm for the new center, stating, “Our new Concord center stands as a testament to our commitment to advancing fertility care, while also ensuring the Concord community has access to the exceptional access to state-of-the-art treatments and groundbreaking innovations in reproductive medicine which they deserve.”
#1 Private Group for Top Doctors in Reproductive Medicine in Massachusetts
#1 Private Group for Top Doctors in Women’s Health in Massachusetts
#1 Private Group for Top Doctors in Reproductive Medicine in the Boston Metro Area
#1 Private Group for Top Doctors in Women’s Health in the Boston Metro Area
Massachusetts has the higher percentage (7%) of babies born as a result of fertility treatment in the US. Boston IVF is a pioneer in the field and having fertility centers close to home and work makes the burden of treatment easier for patients, resulting in greater access to care.
For more information about the new Concord location, its care team, or to schedule an appointment, please visit www.bostonivf.com.
Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include 40 reproductive endocrinologists across nearly 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts. In 2024, Boston IVF joined the global IVI RMA Network, contributing to the network’s management of more than 20+ labs and 60 satellites across North America.
Watch to discover how technology and innovation are beckoning change.
JUPITER, Fla., Sept. 9, 2024 /PRNewswire-PRWeb/ — Tune in to Bloomberg on Saturday, September 14, 2024, to watch a new episode of Advancements, hosted by Ted Danson.
Coming up, learn about the importance of preserving biodiversity as Advancements explores how S.E.A. Aquarium, by Resort World Sentosa (RWS), contributes to research and to the preservation of marine life. See how aquariums act as a platform for education, while discovering how S.E.A. Aquarium provides opportunities for people to engage with and learn about biodiversity, as well as how it promotes education, the importance of marine conservation, and biodiversity as a way to better the state of our oceans.
Next, learn about the need to provide at-risk populations with access to available treatments today. Hearing from experts, viewers will learn how Esperion Therapeutics (Esperion) works to discover, develop, and commercialize innovative medicines to help improve outcomes for patients who are at risk for or have cardiovascular and cardiometabolic diseases, while breaking through the barriers that prevent patients from reaching their heart health goals.
With a look at the demand for mental healthcare in the U.S., audiences will learn about Hero Journey Club (HJC), which brings high-level mental healthcare to those who might not otherwise have had access to traditional care. The show will share how group settings allow HJC mental health practitioners the ability to work with more participants than a one-on-one setting, helping to lower costs and enable more people to get the care they need.
Finally, discover how artificial intelligence is being used to improve brain health diagnosis as the show shares how ViewMind analyzes eye movement patterns to provide a high precision measurement of brain health. Spectators will see how the solution for precision diagnostics and measurement of neurocognitive health is being used to help predict Alzheimer’s before the sign of symptoms appear.
“This episode is full of innovative and engaging content that is sure to enlighten and entertain audiences,” said Chad Densen, production manager for DMG Productions and the Advancements series. “We are excited to share this information with viewers.”
About Advancements and DMG Productions: Advancements is an information-based educational television series that explores recent developments taking place across several industries and economies. Shining a light on important issues and topics, the series features the cutting-edge improvements, state-of-the-art technologies, and innovative environmental and sustainable solutions responsible for shaping, molding, and transforming the world.
DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming for viewers and networks. Focused on the major innovations and advancements responsible for global progress today, its team of award-winning writers, directors, and producers go on location to discover and share how technology and innovation continue to drive the world forward.
“The 30A area is very health and wellness focused so I wanted to bring a Stretch Zone to them,” says Crowell. Kim is excited to expand the Stretch Zone brand footprint in the 30A community and share the unique benefits of assisted stretching with as many people as possible at a prime location.
Stretch Zone is the only nationally-accredited stretch franchise due in large part to its patented equipment and proprietary training and education methodology. Stretch Zone focuses on a scientific approach to stretching and believes in re-educating muscles to establish a more ideal resting muscle tone and range of motion.
Stretch Zone 30A is located at 4688 US Highway 98W, Unit 2A, Santa Rosa Beach, FL. Operating hours are M-F 6am-7pm, Saturday 9am-3pm, and the studio phone number is 850-407-8088. The first visit is free for any new Stretch Zone client. For more information, visit www.stretchzone.com.
About Stretch Zone
Founded in 2004 by Jorden Gold, Stretch Zone is a brand that was built with heart. Revolutionizing how we all approach stretching, the brand is on a mission to improve the quality of life for communities by utilizing their proprietary tables and patented strapping system to assist in achieving long term results. With more than 350 locations open throughout 41 states, this brand has seen incredible growth since its start and has no plans on slowing their momentum, receiving national recognition for their growth in the 2023 Inc. 5000 and Entrepreneur’s 2023 Fastest Growing Franchises. Stretch Zone is looking for experienced franchisees that are passionate about the health and wellness industry and are committed to making a positive impact in the communities they serve. For more information, please visit https://www.stretchzone.com/.
The invention of the car seat has saved an untold number of lives. It’s vital you make use of these seats to keep your child as safe as possible on the road. In recognition of Child Passenger Safety Month, it’s time to learn more about the different types of car seats.
DENVER, Sept. 9, 2024 /PRNewswire-PRWeb/ — The invention of the car seat has saved an untold number of lives. It’s vital you make use of these seats to keep your child as safe as possible on the road. In recognition of Child Passenger Safety Month, it’s time to learn more about the different types of car seats.
There are four recognized stages of child safety in the car. The first is rear facing for newborns through at least 2 years old. The second is forward facing for older toddlers to usually preschool age. The third is belt positioning which is more commonly known as booster seat age. The fourth is when a child fits in the seat belt without a device.
Rear Facing Seat
Rear-facing car seats are used for babies. They offer the maximum level of protection of any car seat and are highly recommended to be used for as long as possible but at least until age two.
In the event of a crash, the rear-facing seat provides a kind of shield around the baby’s body. The padded seat absorbs most of the crash impact, protecting the baby’s head, spine and neck.
A rear-facing car seat is likely made from polypropylene. This is a strong form of plastic that bends some under pressure, instead of cracking. This polypropylene shell is then lined with foam. The foam is specially regulated to ensure it provides adequate protection and flame resistance. Rear facing car seats also feature a 5-point harness to hold the child in the restraint. Correctly positioned harness straps are at or below a child’s shoulder when rear facing.
Babies are extremely vulnerable at this young age, so the extra protection provided by rear-facing seats is vital. If your vehicle crashes into something from the front, the passengers in your car will be forced toward the front of the vehicle. In a rear facing car seat, baby will ride down the crash energy with its spine fully supported.
Some seats allow children to remain rear-facing up to around 50 pounds in weight. For most children, this will keep them covered until at least the age of two. Choose a model with a high weight rating to allow your children to enjoy that greatest protection for as long as possible.
Front Facing Seats
Children can’t stay in rear-facing seats forever. Eventually, they become too large or heavy and must transition into front-facing seats.
Although front-facing seats don’t offer the same high levels of protection as rear-facing seats, they can still protect your child.
Forward facing seats also feature the same polypropylene shell and foam padding as rear-facing seats. Several types of seats (ie. convertible or all-in-one seats) go from rear facing to forward facing by turning the seat around.
The harness section of a car seat also provides a layer of protection. When positioned properly, above the child’s shoulder, and pulled tight to the chest, it holds the child in place, even during a crash. The harness can also help to distribute the force of the crash over a wider area of the body.
For maximum child safety, you will need to choose a seat based on your child’s weight and size.
Booster Seats
Once a forward-facing car seat is no longer viable due to your child’s size or age, they will need to start using a booster seat. Booster seats lift a child up to fit the adult seat belt.
You will also need to think carefully about how your child is belted into the booster seat. Booster seats require a lap-shoulder seat belt. The belt needs to cover your child’s shoulder, chest, and pelvis. It needs to be tight enough to keep the child secured.
High-backed booster seats have a back and often sides. They do not have a fixed harness. Children in these seats use the car’s seatbelt to keep themselves safely secured. The booster helps position the seat belt on the shoulder and across the hips.
Backless booster seats are lighter and more mobile than other high-back booster seats. These do not have a back or sides and are typically used by older school-aged children. It’s just the bottom seat to boost the child up so they can properly use the seatbelt.
Booster seats provide a decent final option for children who are now too big to fit comfortably inside the confines of a car seat but do not yet properly fit just the seat belt.
The Perfect Car Seat for Your Child
Choosing the right car seat is a big decision. But when you’re armed with the right information, you can make the best choice for your needs. Visit our website for more in depth information about determining your child’s stage and selecting the right car seat.
If you’re looking for car seats built with safety in mind, Safe Ride 4 Kids can help. We offer a range of innovative child restraints and recommend other quality car seats. Check out Safe Ride 4 Kids’ store today.
“You are invited on a transformative journey through the Gospel of Luke, a journey that can deepen your understanding, ignite your faith, and soothe the longing in your soul,” said Wilson.
Brad Wilson owns Island Brow Coffee, where he roasts, packages and ships coffee all over the country. He has a bachelor’s degree in psychology from Hardin-Simmons University, and also teaches a Sunday morning Bible study at his church. Wilson and his wife, Laurie have two teenagers and seven cats (yes, seven!).
Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 20,000 titles published to date. With God… is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.
New book addresses the pressure religious leaders face to bury their personal struggles for the benefit of their congregations
SANFORD, Fla., Sept. 9, 2024 /PRNewswire-PRWeb/ — Author, speaker and lay pastor Dr. Susan Agbenoto has released her new book, aimed at those who may be suffering in silence. “Restore Me!: But Privately, Please (The People Cannot Know,) recognizes the pressures of leadership, and the desire for privacy when confronting difficult personal situations.
Agbenoto brings attention to the masks worn by Christian leaders in the ecclesial context. Unlike the Greek theater where everyone, actors and audience alike, were in on the deception for the sake of its entertainment value, the masks encountered in the Church portray public faces that hide private problems. Her intention is not to accuse, demean, or demoralize Christian leaders. Rather, she compassionately reminds readers of their humanity and the need to stay close to the Lord.
“I want to help people find peace, strength and restoration in God,” Agbenoto said. “The idea for the book came to be after I realized that I needed revitalization myself. I spoke with ministers and leaders who had gone through periods of either grief, suffering, or loss and noticed that some had come out stronger while others were on a downward spiral. I wanted to find a way to help them, but without them having to accept help under the scrutiny of the public eye.”
“Restore Me!” offers advice to help readers assess their lives from the inside, without the hindrance of outside perceptions or the need to maintain a certain face to the public. The book acts as a private one-on-one session with Agbenoto, where she gives readers the opportunity to confront problems, pray, and empowers and challenges readers to take the next steps to break free of the internal cage they suffer in.
“Not many books deal with how complex the human soul is,” Agbenoto explained. “You may be caught up in taking care of your congregation, a group of people, or even a single person while facing your own private battles. I want readers to understand that even when you feel like you have reached the end of your rope, there is still hope and steps that you can take to make things better.”
Agbenoto continues to share the grace of God through her recently released book, “New Wine: A Journey into Refueling your Life in the Spirit.” The book offers readers a unique delve into spiritual renewal, providing insights and revelations to ignite one’s passion for a deeper relationship with God.
“Restore Me!: But Privately, Please (The People Cannot Know)” By Dr. Susan Agbenoto ISBN: 9798385017621 (softcover); 9798385017638 (hardcover); 9798385017645 (electronic) Available at WestBow Press, Amazon and Barnes & Noble
About the author Dr. Susan Agbenoto obtained her Doctor of Ministry degree from The United Theological Seminary and has been serving as a lay pastor within a large church network. She uses her curiosity, faith, and love for God and his Word, to immerse readers into a place of restorative hope and renewal. Agbenoto’s conversational tone while explaining practical spiritual concepts makes her books easy to read. Her intertwining passions of prayer and the study of theology translates into a tangible encounter with the divine, leaving readers intellectually stimulated, spiritually refreshed and wanting more. To learn more, please visit http://www.susan-agbenoto.com.
General Inquiries: LAVIDGE – Phoenix Ashley Fletcher [email protected]
The data was reported at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
This is the first analysis of individual patient-level data from two phase 3 trials, CheckMate 77T and CheckMate 816, to examine which patients may derive benefit from adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery for stage I-III NSCLC.
CheckMate 816, which was led by Dr. Patrick Forde of The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Sidney Kimmel Comprehensive Cancer, in Baltimore, MD., evaluated neoadjuvant nivolumab plus chemotherapy. The study demonstrated statistically significant and clinically meaningful improvements in event-free survival and pathological complete response and is the sole approved, neoadjuvant only immunotherapy-based treatment for resectable NSCLC.
Building on this foundation, Dr. Tina Cascone of the MD Anderson Cancer Center, in Houston, and her collaborators developed CheckMate 77T, which assessed perioperative nivolumab, revealing statistically significant and clinically meaningful improvement in event-free survival and a meaningful increase in pathological complete response rate compared to control.
This analysis compared event-free survival from the time of surgery among patients from CheckMate 77T, who received neoadjuvant nivolumab plus chemotherapy followed by definitive surgery and at least one dose of adjuvant nivolumab, with patients from CheckMate 816, who also received neoadjuvant nivolumab plus chemotherapy followed by definitive surgery but without adjuvant nivolumab.
After applying propensity score weights to account for differences in baseline characteristics, perioperative nivolumab (N=139) showed improved event-free survival compared to neoadjuvant nivolumab plus chemotherapy only (N=147). Specifically, the hazard ratios for EFS were 0.61 (weighted ATE) and 0.56 (weighted ATT). Of note, EFS benefit was observed regardless of pCR status although the benefit was clearer in patients without pCR who received additional adjuvant nivolumab treatment after surgery. Benefit was seen regardless of baseline disease stage, with a greater magnitude of benefit in patients with tumor PD-L1 of less than 1 percent. No new safety signals were seen with perioperative nivolumab.
“The individual patient-level data analysis from CheckMate 77T and CheckMate 816 indicates that perioperative nivolumab offers a notable improvement in EFS over neoadjuvant nivolumab plus chemotherapy alone in patients with resectable NSCLC, including those with PD-L1 of less than one percent expression,” reported Dr. Forde. “While the findings should be considered with caution due to the limitations of propensity score weighting, this cross-trial analysis provides compelling evidence supporting perioperative nivolumab as an effective treatment option for resectable NSCLC.” Dr. Cascone added.
“This is the first individual patient-level analysis demonstrating improved efficacy of perioperative nivolumab compared with the standard of care neoadjuvant only nivolumab plus chemotherapy in resectable NSCLC,” she added. “These results should be interpreted with caution given the exploratory nature of the analysis. Nevertheless, the findings are very encouraging and provide a foundation for thoughtful discussions with our patients regarding treatment options for their disease.”
About the IASLC: The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.
About the WCLC: The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results.
The research was reported by Dr. Annette McWilliams, Fiona Stanley Hospital, Australia at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
The PanCan nodule protocol utilises a risk-based approach for triaging participants at the point of screening entry. This model potentially simplifies management by reducing the need for frequent LDCT scans when prior imaging is unavailable. Lung-RADS is a quality assurance tool designed to standardize lung cancer screening CT reporting and management recommendations, reduce confusion in lung cancer screening CT interpretations, and facilitate outcome monitoring.
Effective management of pulmonary nodules detected through low-dose computed tomography screening is crucial for early lung cancer detection and treatment. Traditionally, management strategies have relied on baseline measurements and follow-up imaging. The PanCan approach, unique in its use for biennial screening triage, was compared to the LungRADS v 1.1 approach in this study.
This study evaluated participants from the International Lung Screen Trial who had baseline LDCT scans between August 2016 and July 2021, and who either completed at least two years of follow-up or had a confirmed lung cancer diagnosis. Participants were managed according to the PanCan protocol, and their outcomes were compared to the LungRADS v 1.1 approach. The analysis included a total of 4,494 participants, with cancer diagnoses tracked until May 30, 2024. The study compared the risk categories for both protocols and assessed cancer detection rates and stage distribution at 12 and 24 months.
Out of 4,494 participants, lung cancer was detected in 184 individuals over a mean follow-up period of 57.9 months, with 109 cases identified within the first two years. The PanCan protocol was associated with fewer referrals for diagnostic workup at screening entry (2.8 percent vs. 7.4 percent for LungRADS v 1.1) and demonstrated a significantly better positive predictive value (PPV) for malignancy in high-risk categories (48.0 percent vs. 18.1 percent, P less than 0.00001). Compared to PanCan, the LungRADS v 1.1 approach required 2.63 times as many positive scans to find the same number of lung cancers. The proportion of Stage I disease at 12 and 24 months was similar between the two approaches. Notably, the PanCan protocol enabled triage of 75 percent of participants with lower risk of lung cancer to biennial screening, resulting in 3,381 fewer LDCT scans without compromising the lung cancer stage distribution. The protocol also reduces the number of participants who require specialist referral for diagnostic workup of suspicious lesions.
“This approach shows improved identification of low and high-risk individuals and our findings suggest that adopting the PanCan protocol could streamline lung cancer screening and management processes,” said Dr. McWilliams.
About the IASLC: The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.
About the WCLC: The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results.
